History

View all milestones

• 1948

  Giorgio Kropf, together with a pharmacist friend, founded Farmimport in Trieste — the original core from which Eurospital would later emerge. A historic milestone: the company imports streptomycin from the American company Merck — the first antibiotic successfully used in Italy to treat tuberculosis.

• 1950

  Giorgio Kropf collaborates with industry giant Don Baxter to establish the first Blood Bank in Trieste — the second in Italy after Turin. The infusion solutions line is imported from Baxter, soon becoming one of the company’s flagship products.

• 1952

  Production laboratories are built, and an agreement is reached with London-based Allen & Hanburys to manufacture infusion solutions and other licensed products directly in Trieste on behalf of both pharmaceutical giants.

• 1955

  Licensed production of Haliborange begins — an effective multivitamin and one of the most appreciated and still best-performing pharmaceutical products in Eurospital’s portfolio.

• 1958

  The BAXTER line of intravenous solutions and blood-related equipment is expanded with a range of blood refrigerators and medical-hospital devices. At the same time, Eurospital begins marketing Dequadin Tincture 28 ml and 10 ml, a medication for the treatment of oral cavity inflammations.

• 1962

  Hella Kropf, a great innovator and lifelong partner of Giorgio Kropf — who passed away suddenly — succeeds her husband, becoming one of the first women in Italy to lead a company.

• 1967

  The company permanently relocates to its new — and current — headquarters on Via Flavia.

• 1968

  Stylex, the first disposable syringe, is produced and marketed — a major step forward in the fight against hospital-acquired infections.

• 1970

  Significant production and commercial growth, with the workforce doubling in size.

• 1971

  Hella Kropf, as President, founds the Tre Venezie Delegation of A.I.D.D.A. (Italian Association of Women Entrepreneurs and Company Executives), affiliated with F.C.E. (Les Femmes Chefs d’Entreprises Mondiales).

• 1979

  Michele Kropf, son of Giorgio and Hella, joins the company, marking the beginning of a new chapter. Eurospital strengthens its position in the Pharmaceutical and Hospital sectors.

• 1984

  The company name is changed to Eurospital Pharma.

• 1986

  The Research & Development department is established and takes on a central role in the diagnostics field, with the goal of introducing innovative Eurospital-branded products both in Italy and abroad. On 20/11/1986, the first in a long line of diagnostic kits entirely developed and produced by EUROSPITAL is released.

• 1988

  Company leadership is passed on to Dr. Michele Kropf, the founder’s son, and the business is reorganized into three divisions: Pharmacy, Diagnostics, and Hospital.

• 1989

  In collaboration with Burlo Garofolo and the Universities of Naples and Trieste, αGliatest IgA is developed and produced — the first innovative in vitro test for detecting antibodies to gluten, responsible for the onset of Celiac Disease.

• 1990

  The Sterilens line is launched — the first range of contact lens solutions available in pharmacies — and Eurospital acquires ownership of the brands for Eurospital Infusion Solutions, Haliborange, Dequadin, Torch, and Non Ad Garze.
  
  The Hospital Division develops Euroset, the first dual-scale flow regulator for the controlled administration of medications. The device is adopted by hospitals and healthcare centers.

• 1995

  First Italian company in the sector to certify its Quality System for the production of in vitro diagnostics in accordance with ISO 9001:1994 standards.

• 1997

  Eurospital acquires the exclusive worldwide license for the use of tissue transglutaminase as a specific marker for the diagnosis of celiac disease, enabling the development of the innovative Eu-tTG IgA test.

• 2000

  Eurospital’s laboratories develop Calprest, an in vitro test for measuring fecal calprotectin concentration. Within fifteen years, it becomes an international benchmark for the non-invasive detection of intestinal inflammation.

• 2008

  From Eurospital’s twenty-year commitment to the study and diagnosis of celiac disease comes a food brand specifically designed for people with celiac disease: Piaceri Mediterranei.

• 2013

  Leadership at Eurospital now directly involves the third generation: Massimiliano and Giulia Kropf, children of Michele and grandchildren of founder Giorgio.

• 2017

  First company to receive FDA certification for the Calprotectin test used in the diagnosis of Inflammatory Bowel Diseases (IBD). Eurospital becomes the first company in the sector in Italy to obtain TÜV America certification for meeting the requirements of the MDSAP program for the United States and Canada.

• 2018

  Eurospital celebrates its 70th anniversary.
  Watch the video on Youtube

• 2020-21

  Ongoing commitment from Eurospital in supporting Italian laboratories and pharmacies in the fight against Sars-CoV-2, through innovative and high-quality products.

• 2022

  Eurospital is among the first Italian companies to receive the IVDR Certificate for in vitro diagnostic medical devices from TÜV SÜD, one of the world’s leading providers of medical device certification and approval.

• 2023

  75th Anniversary Milestone and First Sustainability Report

• 2024

  The new Special Nutrition Division is established with the launch of Apromé, a line of low-protein products.